{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:27:01Z","timestamp":1790620021622,"version":"4.1.0"},"reference-count":15,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2015.01320","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T01:18:45Z","timestamp":1448932725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":70,"title":["Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration \u201cAnimal Rule\u201d"],"prefix":"10.3389","volume":"6","author":[{"given":"Chia-Wei","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"key":"B15","author":"Subpart","year":"2015"},{"key":"B1","first-page":"27","article-title":"Raxibacumab for anthrax","volume":"55","year":"2013","journal-title":"Med. Lett. Drugs Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3,1004","DOI":"10.3390\/toxins3081004","article-title":"Monoclonal antibody therapies against anthrax","author":"Chen","year":"2011","journal-title":"Toxins (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1600-065X.2010.00969.x","article-title":"Progress and novel strategies in vaccine development and treatment of anthrax","volume":"239","author":"Chitlaru","year":"2011","journal-title":"Immunol. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/toxins5010120","article-title":"Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin\/Raxibacumab-treated New Zealand white rabbits","volume":"5","author":"Corey","year":"2013","journal-title":"Toxins (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.micinf.2011.07.005","article-title":"Key aspects of the molecular and cellular basis of inhalational anthrax","volume":"13","author":"Cote","year":"2011","journal-title":"Microbes Infect"},{"key":"B6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1086\/427189","article-title":"Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis","volume":"191","author":"Cui","year":"2005","journal-title":"J. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.7326\/0003-4819-144-4-200602210-00009","article-title":"Systematic review: a century of inhalational anthrax cases from 1900 to 2005","volume":"144","author":"Holty","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002: updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Bio-terrorism-related inhalational anthrax: the first 10 cases reported in the United States","volume":"7","author":"Jernigan","year":"2001","journal-title":"Emerging Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4161\/mabs.1.6.10195","article-title":"Raxibacumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"MAbs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1128\/AAC.04606-14","article-title":"Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax","volume":"59","author":"Migone","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the treatment of inhalational anthrax","volume":"361","author":"Migone","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1086\/430708","article-title":"A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers","volume":"41","author":"Subramanian","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B14","first-page":"1","article-title":"Centers for Disease Control and Prevention. Use of anthrax vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"59","author":"Wright","year":"2010","journal-title":"MMWR Recomm Rep"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"deposited":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T01:18:45Z","timestamp":1448932725000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmicb.2015.01320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,1]]},"references-count":15,"URL":"https:\/\/doi.org\/10.3389\/fmicb.2015.01320","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,1]]}}}